Last updated on December 2018

An Investigational Immunotherapy Study of Nivolumab With Standard of Care Therapy vs Standard of Care Therapy for First-Line Treatment of Colorectal Cancer That Has Spread


Brief description of study

This purpose of this study is to evaluate nivolumab (BMS-936558) in combination with standard of care (SOC) chemotherapy with bevacizumab for the treatment of first-line metastatic colorectal cancer (mCRC).

Clinical Study Identifier: NCT03414983

Find a site near you

Start Over

Local Institution

New York, NY United States
6.76miles
  Connect »